Biocept has partnered with Quest Diagnostics to offer its Target Selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the latter’s customers.
The less invasive, lab-developed assay is used to perform genomic profiling in advanced non-small cell lung cancer (NSCLC) patients for facilitating advanced targeted treatments and analysing the therapy’s effectiveness.
The panel has the most common clinically actionable genes for NSCLC. It merges Biocept’s liquid biopsy biomarker testing capabilities with NGS and decision support resources.
